Fig. 4.

AFGd-LDH reduces ischemic stroke infarct areas through decreasing ROS-caused oxidative damage. (a) Cerebral blood flow (CBF) measured by laser speckle imaging in a tMCAO mice model before and after restored perfusion for 18 h. (b) In vivo imaging of Gd-LDH and AFGd-LDH, respectively. (c–d) Photoacoustic imaging of tMCAO mice before and after the injection of AFGd-LDH. (e) MRI imaging of tMCAO mice before and after the injection of AFGd-LDH. (f) Photographs of brain slices by TTC-stained after cure with sample (n = 3). (g) Resultant infarct zones of various treatment determined by imaging (n = 3). (h) Neurological deficit scores of tMCAO mice by different treatments at 3 days (n = 3). *p < 0.05, **p < 0.01 and ***p < 0.001.